Could Fish Oil Be a Secret Weapon Against Type 2 Diabetes?

Fish Oil Steps Into the Diabetes Spotlight

Most conversations about type 2 diabetes circle back to one word: obesity. But a growing body of research is challenging that narrow view — and fish oil may be at the center of the shift. A Brazilian study published in the journal Nutrients has found that omega-3 fatty acids derived from fish oil can significantly reduce insulin resistance in diabetic rats that were not obese, opening a new window into how this common condition develops and how it might be treated.

The research was funded by FAPESP, Brazil's São Paulo Research Foundation, and focused on a specific animal model known as Goto-Kakizaki (GK) rats — a well-established laboratory tool for studying non-obese type 2 diabetes. The findings suggest that inflammation, not just body fat, may be a critical driver of insulin resistance — and that omega-3 supplementation could help reverse that process.

The Overlooked Face of Type 2 Diabetes

Type 2 diabetes is widely associated with excess weight, and for good reason — obesity remains one of its strongest risk factors. However, it is far from the only path to the disease. Estimates suggest that between 10% and 20% of people living with type 2 diabetes worldwide are not obese. In these individuals, the biological mechanisms behind insulin resistance may operate quite differently from those seen in overweight patients.

Insulin is the hormone responsible for guiding glucose out of the bloodstream and into cells where it can be used for energy. When cells stop responding properly to insulin, blood sugar rises and the body struggles to maintain metabolic balance. In obese individuals, excess fat tissue releases pro-inflammatory molecules that disrupt insulin signaling. But what drives the same process when there is no excess fat?

That question is precisely what the Brazilian research team set out to answer.

What the Study Found

Researchers administered fish oil to GK rats at a dose of 2 grams per kilogram of body weight — containing approximately 540 mg/g of eicosapentaenoic acid (EPA) and 100 mg/g of docosahexaenoic acid (DHA) — three times per week over an eight-week period.

The results were striking. By the study's end, the rats receiving omega-3 supplementation showed:

• Lower insulin resistance
• Improved blood sugar regulation
• Reduced inflammatory markers
• Better lipid profiles, including lower total cholesterol, LDL (commonly known as "bad" cholesterol), and triglycerides

Perhaps most significantly, the fish oil appeared to shift the behavior of immune cells — specifically lymphocytes — away from a pro-inflammatory state and toward an anti-inflammatory one.

The Immune System Connection

Lymphocytes are white blood cells that play a central role in directing the body's adaptive immune response. When they operate in a chronically inflamed state, the damage can cascade through the entire immune system and worsen metabolic conditions.

"We found that insulin resistance can be reduced in these animals by modulating the inflammatory response so as to change the profile of defense cells from a pro-inflammatory state to an anti-inflammatory state," said Rui Curi, Director of Butantan Institute's Education Center and coordinator of the study. He noted that this mirrors how omega-3 supplementation has been observed to work in obese individuals with insulin resistance.

The study found that fish oil reduced the activity of Th1 and Th17 lymphocyte subtypes — both known to fuel inflammation — while increasing the proportion of regulatory T-cells (Tregs), which help suppress harmful immune activation.

"Fish oil supplementation reversed this pro-inflammatory profile, displaying a significant anti-inflammatory effect," said Tiago Bertola Lobato, the PhD candidate who led the study. "The action of omega-3 fatty acids on lymphocytes, modulating them from a pro-inflammatory state to an anti-inflammatory state, may have triggered the reduction in insulin resistance in these animals."

Inflammation as a Hidden Engine of Diabetes

One of the study's most important contributions is reinforcing the idea that insulin resistance is not purely a metabolic disorder — it is also deeply intertwined with immune function. Chronically elevated inflammatory signals can directly interfere with insulin signaling pathways, making it harder for cells to respond to the hormone even in the absence of obesity.

Earlier work by the same research group had already identified signs of systemic inflammation in non-obese GK rats, including elevated pro-inflammatory cytokines from both lymphocytes and macrophages. A related paper published in FEBS Letters found that anti-inflammatory defenses begin to break down remarkably early in these animals — with 21-day-old GK pups already showing reduced markers of regulatory T-cells in their lymph nodes.

"In the non-obese model, the impactful characteristic of adipose tissue is absent, but systemic inflammation is present," Curi explained, underscoring that the inflammatory process in non-obese diabetes operates through different channels than in obesity but can be equally damaging.

Human Research Adds Supporting Evidence

While the Brazilian study was conducted in animals, recent human trials are adding weight to the hypothesis that omega-3s may meaningfully affect insulin resistance and metabolic health.

A 2025 double-blind randomized controlled trial published in Food and Function tested fish oil supplementation in healthy middle-aged and older adults over 12 weeks. Participants in the fish oil groups showed dose-related increases in serum EPA and DHA, along with decreases in fasting insulin and HOMA-IR — a widely used marker of insulin resistance. Fasting blood glucose and several lipid-related measures also trended in a favorable direction.

A 2024 analysis published in Nutrition and Diabetes, drawing on data from 161 patients with type 2 diabetes, found a dose-related association between omega-3 intake and HbA1c, a long-term indicator of blood sugar control. The authors suggested that omega-3 supplementation could eventually be studied in a more personalized, individualized framework — though they also acknowledged that the overall role of omega-3s in diabetes management remains a subject of scientific debate.

Important Caveats: Animal Studies Are Not the Final Word

Despite the promising signals, researchers were careful to urge caution. Preclinical results from animal studies do not automatically translate to the same outcomes in humans. Clinical trials in people with non-obese type 2 diabetes are still needed before omega-3 supplementation can be recommended as a treatment strategy for this group.

"These studies involved well-established experimental models that mimic insulin resistance in non-obese individuals. Trials in humans are needed to estimate the ideal dose and the most indicated type of omega-3 fatty acid," Curi said.

Renata Gorjão, co-author of the study and Co-Director of UNICSUL's Program of Graduate Studies in Health Sciences, echoed this sentiment: "Our findings increased our knowledge of the link between inflammation and insulin resistance in non-obese animals, confirming that this is a key factor in diabetes even in the absence of obesity."

A New Way of Thinking About Diabetes Risk

Taken together, these findings suggest that the story of type 2 diabetes is more complex — and more nuanced — than the conventional obesity-centered narrative. Body weight matters enormously, but it is not the whole picture. For the millions of people worldwide who develop diabetes without excess weight, inflammation may be the central villain, and targeting it through dietary interventions like omega-3 supplementation could prove to be a meaningful piece of the puzzle.

Fish oil will not replace established diabetes treatments anytime soon, and human evidence remains mixed. But as science continues to explore the intricate relationship between the immune system and metabolic health, omega-3 fatty acids are earning a place in the conversation — not just as a supplement for heart health, but as a potential tool in the broader fight against diabetes.